The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Open accessAbstract
Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 3×
“Notably, the combination of fulvestrant and alpelisib has shown synergistic antitumor activity against ER+/PIK3CAmutated advanced BC (André et al., 2019).”
BackgroundResultmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Breast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 863
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706 · cited 2×
“Moreover, PI3K inhibition can result in hyperglycaemia as PI3K mediates cellular responses to insulin, which leads to an increasing release of insulin in a feedback manner and re-activate PI3K pathway in tumor models in mice, thus ultimately causing PI3Ki resistance (Hopkins et al., 2018).”
BackgroundBachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.-M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545
Baselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
Yardley, D. A., Noguchi, S., Pritchard, K. I., Burris, H. A., Baselga, J., Gnant, M., Hortobagyi, G. N., Campone, M., Pistilli, B., Piccart, M., et al. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0060-1 · Cited by 522
Breast Cancer: Current Molecular Therapeutic Targets and New Players
Nagini, S. (2017) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520616666160502122724 · Cited by 503
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493
T-bet: a bridge between innate and adaptive immunity
Lazarevic, V., Glimcher, L. H., & Lord, G. M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3536 · Cited by 486
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Self-citationJuvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 462
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4697-y · Cited by 439
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Self-citationPI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Guerrero-Zotano, A., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 417
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4879 · Cited by 413
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 348
Miller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0101 · Cited by 346
Molecular mechanisms of drug resistance and its reversal in cancer
Kartal-Yandim, M., Adan-Gokbulut, A., & Baran, Y. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1015957 · Cited by 346
Chemoresistance mechanisms of breast cancer and their countermeasures
Ji, X., Lu, Y., Tian, H., Meng, X., Wei, M., & Cho, W. C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108800 · Cited by 340
Mayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D., Berger, M. F., Won, H. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0134 · Cited by 319
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 306
Patton, D. T., Garden, O. A., Pearce, W. P., Clough, L. E., Monk, C. R., Leung, E., Rowan, W. C., Sancho, S., Walker, L. S. K., Vanhaesebroeck, B., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6598 · Cited by 303
Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M., Johnston, S., Morales, S., Yardley, D. A., Melichar, B., Forero-Torres, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295
Wolff, A. C., Lazar, A. A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L., Sun, Y., Neskovic-Konstantinovic, Z., Guimaraes, R. C., Fumoleau, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 272
Alpelisib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01161-6 · Cited by 270
O'Brien, C., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 255
Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K.-M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2653 · Cited by 244
Arribas, J., Baselga, J., Pedersen, K., & Parra-Palau, J. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3795 · Cited by 236
Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp304 · Cited by 231
Jones, R. H., Casbard, A., Carucci, M., Cox, C., Butler, R., Alchami, F., Madden, T.-A., Bale, C., Bezecny, P., Joffe, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30817-4 · Cited by 229
Efficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Bitler, B. G., Watson, Z. L., Wheeler, L. J., & Behbakht, K. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.003 · Cited by 217
Drugging PI3K in cancer: refining targets and therapeutic strategies
Yap, T. A., Bjerke, L., Clarke, P. A., & Workman, P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.016 · Cited by 202
Tazzari, P. L., Cappellini, A., Ricci, F., Evangelisti, C., Papa, V, Grafone, T., Martinelli, G., Conte, R., Cocco, L., McCubrey, J. A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404523 · Cited by 196
Talazoparib: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-1026-z · Cited by 193
PI3K mutations in breast cancer: prognostic and therapeutic implications
Mukohara, T. (2015) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s60696 · Cited by 190
Sanchez, C. G., Ma, C. X., Crowder, R. J., Guintoli, T., Phommaly, C., Gao, F., Lin, L., & Ellis, M. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2833 · Cited by 184
Luo, J., Yao, J.-F., Deng, X.-F., Zheng, X.-D., Jia, M., Wang, Y.-Q., Huang, Y., & Zhu, J.-H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0694-6 · Cited by 182
Martín, M., Chan, A., Dirix, L., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180
Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquiere, N., Bradley, E., Bull, R., Do, S., Dotson, J., Dudley, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 179
Razis, E., Bobos, M., Kotoula, V., Eleftheraki, A. G., Kalofonos, H. P., Pavlakis, K., Papakostas, P., Aravantinos, G., Rigakos, G., Efstratiou, I., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1572-5 · Cited by 177
Mayer, I. A., Abramson, V. G., Isakoff, S. J., Forero, A., Balko, J. M., Kuba, M. G., Sanders, M. E., Yap, J. T., Van den Abbeele, A. D., Li, Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0518 · Cited by 177
Michaloglou, C., Crafter, C., Siersbaek, R., Delpuech, O., Curwen, J. O., Carnevalli, L. S., Staniszewska, A. D., Polanska, U. M., Cheraghchi-Bashi, A., Lawson, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0537 · Cited by 177
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
Eid, R. A., Samara, R. N., Ozbun, L. L., Abdalla, M. Y., Berzofsky, J. A., Friedman, K. M., Mkrtichyan, M., & Khleif, S. N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0095 · Cited by 167
Tapodi, A., Debreceni, B., Hanto, K., Bognar, Z., Wittmann, I., Gallyas, F., Varbiro, G., & Sumegi, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507075200 · Cited by 166
PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
Bazzichetto, C., Conciatori, F., Pallocca, M., Falcone, I., Fanciulli, M., Cognetti, F., Milella, M., & Ciuffreda, L. (2019) · Cancers · doi:10.3390/cancers11040435 · Cited by 164
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. H., Prudkin, L., Sánchez, G., Rodríguez, O., Antón, P., Parra, J.-L., Marlow, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66343 · Cited by 154
Zhang, L., Li, Y., Wang, Q., Chen, Z., Li, X., Wu, Z., Hu, C., Liao, D., Zhang, W., & Chen, Z.-S. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1112-1 · Cited by 152
Sabine, V. S., Crozier, C., Brookes, C. L., Drake, C., Piper, T., van de Velde, C. J. �., Hasenburg, A., Kieback, D., Markopoulos, C. J., Dirix, L. Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8272 · Cited by 136
O’Brien, N. A., McDonald, K., Luo, T., von Euw, E., Kalous, O., Conklin, D. F., Hurvitz, S. A., di Tomaso, E., Schnell, C., Linnartz, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2769 · Cited by 129
Veres, B., Gallyas, F., Várbiró, G., Berente, Z., Ősz, E., Szekeres, G., Szabó, C., & Sümegi, B. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00077-7 · Cited by 126
Veres, B., Radnai, B., Gallyas, F., Várbiró, G., Berente, Z., Ősz, E., & Sümegi, B. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065151 · Cited by 122
Vuylsteke, P., Huizing, M. T., Petráková, K., Roylance, R. R., Laing, R. W., Chan, S. Y. T., Abell, F., Gendreau, S. B., Rooney, I. A., Apt, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw320 · Cited by 120
Pogue–Geile, K. L., Song, N., Jeong, J., Gavin, P. G., Kim, S.-R., Blackmon, N. L., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2439 · Cited by 119
van der Waart, A. B., van de Weem, N. M. P., Maas, F., Kramer, C. S. M., Kester, M. G. D., Falkenburg, J. H. F., Schaap, N. P., Jansen, J. H., van der Voort, R., Gattinoni, L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578583 · Cited by 116
Shang-Hsun, T., Chen, T.-M., Hsiao, H.-T., & Chen, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116747 · Cited by 111
Self-citationTargeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Cidado, J. R., & Park, B. H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9264-2 · Cited by 108
Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
Zhang, J., Xu, K. L., Liu, P., Geng, Y., Wang, B., Gan, W., Guo, J., Wu, F., Chin, Y. R., Berrios, C. J., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.023 · Cited by 108
Loibl, S., de la Peña, L., Nekljudova, V., Zardavas, D., Michiels, S., Denkert, C., Rezai, M., Bermejo, B., Untch, M., Lee, S. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.020 · Cited by 103
Hu, Y., Guo, R., Wei, J., Zhou, Y., Ji, W., Liu, J., Zhi, X., & Zhang, J. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.363 · Cited by 98
Schmid, P., Pinder, S. E., Wheatley, D. A., Macaskill, J., Zammit, C., Hu, J. J., Price, R., Bundred, N. J., Hadad, S. M., Shia, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9179 · Cited by 97
Brandão, M., Caparica, R., Eiger, D., & de Azambuja, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz280 · Cited by 93
Yu, C., Hung, S., Lin, H., Chiou, W., Lee, M., Liao, H., Huang, H., Ho, H.-C., & Su, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.19817 · Cited by 92
Dornan, G. L., & Burke, J. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00575 · Cited by 86
Dey, N., Williams, C. B., Leyland-Jones, B., & De, P. K. (2015) · PubMed · Cited by 79
Stern, H. M., Gardner, H., Burzykowski, T., Elatre, W. A., O'Brien, C. L., Lackner, M. R., Pestano, G. A., Santiago, A., Villalobos, I. E., EIERMANN, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2993 · Cited by 75
Olaparib for the treatment of breast cancer
Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1458613 · Cited by 72
Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer
Gao, C., Yuan, X., Jiang, Z., Gan, D., Ding, L., Sun, Y., Zhou, J., Xu, L., Liu, Y., & Wang, G. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05239-3 · Cited by 72
Beelen, K. J., Opdam, M., Severson, T., Koornstra, R. H. T., Vincent, A. D., Wesseling, J., Muris, J. J. F., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3606 · Cited by 71
The Role of CDK4/6 Inhibitors in Breast Cancer
Murphy, C. G. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0651-4 · Cited by 68
Wanigasooriya, K., Tyler, R., Barros-Silva, J. D., Sinha, Y., Ismail, T., & Beggs, A. D. (2020) · Cancers · doi:10.3390/cancers12051278 · Cited by 65
Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer
Zhao, M., & Ramaswamy, B. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.248 · Cited by 63
Brünner-Kubath, C., Shabbir, W., Saferding, V., Wagner, R., Singer, C. F., Valent, P., Berger, W., Marian, B., Zielinski, C. C., Grusch, M., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1232-1 · Cited by 62
Hanamura, T., & Hayashi, S. (2017) · Breast Cancer · doi:10.1007/s12282-017-0772-1 · Cited by 58
Chen, Q., Wang, Z., Zhu, L., Yao, D., Wang, C., Song, Y., Hu, S., Liu, H., Bai, Y., Pan, Y., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00232 · Cited by 58
Brady, S. W., Zhang, J., Tsai, M.-H., & Yu, D. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2014.1002693 · Cited by 56
Mollon, L. E., Anderson, E. J., Dean, J. L., Warholak, T. L., Aizer, A. A., Platt, E., Tang, D. H., & Davis, L. E. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.08.011 · Cited by 55
Ramirez-Ardila, D. E., Helmijr, J., Look, M. P., Lurkin, I., Ruigrok-Ritstier, K., Laere, S. V., Dirix, L. Y., Sweep, F. C. G. J., Span, P. N., Linn, S. C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2529-7 · Cited by 53
Elster, N., Cremona, M., Morgan, C., Toomey, S., Carr, A., O’Grady, A., Hennessy, B. T., & Eustace, A. J. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3239-5 · Cited by 52
Wang, H., Jia, X.-H., CHEN, J.-R., Wang, J., & Li, Y. (2016) · Oncology Reports · doi:10.3892/or.2016.4730 · Cited by 52
Gayle, S. S., Arnold, S. L. M., O'Regan, R. M., & Nahta, R. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799015002 · Cited by 51
PI3K inhibition to overcome endocrine resistance in breast cancer
Keegan, N. M., Gleeson, J. P., Hennessy, B. T., & Morris, P. G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417384 · Cited by 51
Li, X., Xu, Y., Ding, Y., Li, C., Zhao, H. W., Wang, J., & Meng, S. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0862-5 · Cited by 50
Liu, L., Meng, T., Zheng, X., Liu, Y., Hao, R., Yan, Y., Chen, S., You, H., Xing, J., & Dong, Y. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0261 · Cited by 49
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
Wang, Q., Liu, P., Spangle, J. M., Von, T., Roberts, T. M., Lin, N., Krop, I. E., Winer, E. P., & Zhao, J. J. (2015) · Oncogene · doi:10.1038/onc.2015.406 · Cited by 48
Xi, J., & Ma, C. X. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00917-8 · Cited by 47
Kulkarni, A. A., Natarajan, S. K., Chandrasekar, V., Pandey, P. R., & Sengupta, S. (2016) · ACS Nano · doi:10.1021/acsnano.6b01600 · Cited by 42
Tapodi, A., Bognár, Z., Szabó, C., Gallyas, F., Sümegi, B., & Hocsák, E. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.005 · Cited by 42
Grizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & Petrelli, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202965 · Cited by 41
Schötz, U., Balzer, V., Brandt, F.-W., Ziemann, F., Subtil, F. S. B., Rieckmann, T., Köcher, S., Engenhart‐Cabillic, R., Dikomey, E., Wittig, A., et al. (2020) · Cancers · doi:10.3390/cancers12020467 · Cited by 41
Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
Sun, C., Zhang, F., Xiang, T., Chen, Q., Pandita, T. K., Huang, Y., Hu, M. C. ‐., & Yang, Q. (2014) · Oncotarget · doi:10.18632/oncotarget.1952 · Cited by 40
Dong, C., Chen, Y., Li, H., Yang, Y., Zhang, H., Ke, K., Shi, X., Liu, X., Li, L., Ma, J., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.32625 · Cited by 39
Self-citationQiu, N., He, Y., Zhang, S., Zhan, Y., Han, G., Jiang, M., He, W., Zhou, J., Liang, H., Ao, X., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.008 · Cited by 36
Chen, K., Shang, Z., Dai, A.-L., & Dai, P.-L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117816 · Cited by 34
Coughlin, C. M., Johnston, D. S., Strahs, A. L., Burczynski, M. E., Bacus, S. S., Hill, J. E., Feingold, J. M., Zacharchuk, C., & Berkenblit, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1108-4 · Cited by 33
The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells
Glorieux, M., Dok, R., & Nuyts, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-73249-z · Cited by 31
Hosford, S. R., Dillon, L. M., Bouley, S. J., Rosati, R., Yang, W., Chen, V. S., Demidenko, E., Morra, R. P., & Miller, T. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2764 · Cited by 30
Marks, D. K., Gartrell, R. D., Asmar, M. E., Boboila, S., Hart, T. D., Lu, Y., Pan, Q., Yu, J., Hibshoosh, H. H., Guo, H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00968 · Cited by 27
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
Owusu‐Brackett, N., Zhao, M., Akçakanat, A., Evans, K. W., Yuca, E., Dumbrava, E. I., Jankú, F., & Meric‐Bernstam, F. (2020) · Oncotarget · doi:10.18632/oncotarget.27503 · Cited by 26
PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.
Huang, D., Tang, L., Yang, F., Jin, J., & Guan, X. (2019) · PubMed · Cited by 25
Immunotherapy for Breast Cancer: First FDA Approved Regimen
Hopital Femme Mere Enfant, H. C. D. L., Soare, C. A., & Soare, C. (2019) · Discoveries · doi:10.15190/d.2019.4 · Cited by 24
Zou, Z., Zhang, J., Zhang, H., Liu, H., Li, Z., Cheng, D., Chen, J., Liu, L., Ni, M., Zhang, Y. X., et al. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.936870 · Cited by 23
Fatehi, D., Soltani, A., & Ghatrehsamani, M. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.04.001 · Cited by 22
The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients
Chen, K., Quan, J., Yang, J., & Chen, Z. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02163-2 · Cited by 20
Dong, C., Chen, Y., Ma, J., Yang, R., Li, H., Liu, R., You, D., Luo, C., Li, H., Yang, S., et al. (2020) · PubMed · Cited by 19
Self-citationLiu, S., Tang, Y., Yan, M., & Jiang, W. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0563-3 · Cited by 15
Zhang, H., Yu, N., Chen, Y., Yan, K., & Wang, X. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28574 · Cited by 11
Self-citationPIK3CA gene mutations in breast carcinoma in Malaysian patients
Leong, V. C., Jabal, M. F., Leong, P. P., Abdullah, M. A., Gul, Y. A., & Seow, H. F. (2008) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2008.07.005 · Cited by 10
Zhang, C., Xu, B.-F., & Liu, P. (2016) · Tumor Biology · doi:10.1007/s13277-016-5381-7 · Cited by 8
Cited by
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
Ansari, M. A., Thiruvengadam, M., Venkidasamy, B., Alomary, M. N., Salawi, A., Chung, I.-M., Shariati, M. A., & Rebezov, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.005 · Cited by 63
Noji, R., Tohyama, K., Nakamura, S., Naito, T., Oikawa, Y., Kuroshima, T., Tomioka, H., Michi, Y., Ikeda, S., Asakage, T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010235 · Cited by 11
Metadata
- Authors
- Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-15
- Volume
- 12
- Pages
- 628690-628690
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3138840859
- Cited by
- 375
- References
- 131
- FWCI
- 15.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.